|
|
|
Home >
Health Conditions > Diabetes > Invokana
(canagliflozin)
Invokana (canagliflozin)
Related Topics:
Where to purchase:
News & Research:
-
Effects of different doses
of canagliflozin on blood pressure and lipids in patients with type 2 diabetes:
a meta-analysis - J Hypertens 2022 Feb 25 -
"Compared with placebo, canagliflozin 100 mg reduced SBP by 3.43 mmHg and DBP by
1.05 mmHg. Canagliflozin 100 mg increased LDL-C by 0.10 mmol/l and HDL
cholesterol (HDL-C) by 0.05 mmol/l. Compared with placebo, canagliflozin 300 mg
reduced SBP by 4.75 mmHg and DBP by 1.69 mmHg. Canagliflozin 300 mg increased
LDL-C by 0.16 mmol/l and HDL-C by 0.06 mmol/l. Compared with canagliflozin 100
mg, canagliflozin 300 mg further reduced SBP by 1.21 mmHg and DBP by 0.64 mmHg,
and further increased LDL-C by 0.06 mmol/l and HDL-C by 0.02 mmol/l. Compared
with placebo and canagliflozin 100 mg, canagliflozin 300 mg increased the risk
of UTI" - See
canagliflozin at ReliableRXPharmacy.
-
The
diabetes medication that could revolutionize heart failure treatment -
Science Daily, 12/1/21 - "For many years there was not a
single medicine that could improve the outcome in patients with the second type
of heart failure -- those patients with preserved ejection fraction ... SGLT2
inhibitors are more commonly known under their trade-names Forxiga
(Dapagliflozin), Invokana (Canagliflozin), and Jardiance (Empagliflozin) ... We
found that patients taking SGLT2 inhibitors were 22 per cent less likely to die
from heart-related causes or be hospitalised for heart failure exacerbation than
those taking placebo" - See
dapagliflozin at reliablerxpharmacy.com.
-
Canagliflozin Improves HF
Symptoms in Fully Remote Trial - Medscape, 11/16/21
-
Canagliflozin Reduces
Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the
Randomized CREDENCE Trial - Am J Kidney Dis 2021 May 21 -
"acute kidney injury (AKI ... Full recovery of
kidney function within 30 days after an AKI event occurred more frequently
with canagliflozin versus placebo (53.1% vs 35.4% ... Canagliflozin compared
to placebo was associated with a reduced incidence of serious and
non-serious kidney-related AEs in patients with T2DM and CKD"
-
FDA Approves
Canagliflozin, a First-in-Class Diabetes Drug - Medscape, 3/29/13 -
"Canagliflozin is the first in a new class of drug,
an oral inhibitor of sodium glucose cotransporter 2 (SGLT2). Inhibition of
SGLT2 reduces resorption of glucose in the kidney, resulting in increased
urinary glucose excretion, with a consequent lowering of plasma glucose
levels as well as weight loss ... But the panel voted 8 to 7 at the same
meeting that it had concerns about the cardiovascular safety of
canagliflozin, most particularly a possible elevated risk for stroke. In the
end, they deemed that current data were insufficient to be certain about
this risk and concluded that longer-term follow-up will be required,
including completion of the Canagliflozin Cardiovascular Assessment Study
(CANVAS)"
Abstracts:
-
Neuroprotective effects of
Canagliflozin: Lessons from aged genetically diverse UM-HET3 mice - Aging
Cell 2022 Jun 15 - "The aging brain is characterized by
progressive increases in neuroinflammation and central insulin resistance, which
contribute to neurodegenerative diseases and cognitive impairment. Recently, the
Interventions Testing Program demonstrated that the anti-diabetes drug,
Canagliflozin (Cana), a sodium-glucose transporter 2 inhibitor, led to lower
fasting glucose and improved glucose tolerance in both sexes, but extended
median lifespan by 14% in male mice only. Here, we show that Cana treatment
significantly improved central insulin sensitivity in the hypothalamus and the
hippocampus of 30-month-old male mice. Aged males produce more robust
neuroimmune responses than aged females. Remarkably, Cana-treated male and
female mice showed significant reductions in age-associated hypothalamic gliosis
with a decrease in inflammatory cytokine production by microglia ... Thus, Cana
treatment improved insulin responsiveness in aged male mice. Furthermore, Cana
treatment improved exploratory and locomotor activity of 30-month-old male but
not female mice. Taken together, we demonstrate the sex-specific neuroprotective
effects of Cana treatment, suggesting its application for the potential
treatment of neurodegenerative diseases" - See
canagliflozin at ReliableRXPharmacy.
-
Effects of canagliflozin on
serum potassium in people with diabetes and chronic kidney disease: the CREDENCE
trial - Eur Heart J 2021 Aug 23 - "Hyperkalaemia is
a common complication of type 2 diabetes mellitus (T2DM) and limits the optimal
use of agents that block the renin-angiotensin-aldosterone system, particularly
in patients with chronic kidney disease (CKD). In patients with CKD,
sodium‒glucose cotransporter 2 (SGLT2) inhibitors provide cardiorenal
protection, but whether they affect the risk of hyperkalaemia remains uncertain
... Among patients treated with renin-angiotensin-aldosterone system inhibitors,
SGLT2 inhibition with canagliflozin may reduce the risk of hyperkalaemia in
people with T2DM and CKD without increasing the risk of hypokalaemia"
-
Effects of 1-year Treatment
with Canagliflozin on Body Composition and Total Body Water in Patients with
Type 2 Diabetes - Diabetes Obes Metab 2021 Aug 2 -
"107 patients with type 2 diabetes were treated with canagliflozin 100 mg, as
add-on therapy, for 12 months ... plasma volume (PV) ... Body weight showed a
significant decrease from 1 month to 12 months of treatment with canagliflozin,
with a higher rate of decrease in body fat in body composition. A significant
decrease in mineral mass was also observed, but its rate was low. Following
treatment with canagliflozin, changes in total body water did not affect
intracellular water, and a significant decrease in extracellular water,
including plasma components, was observed early and was sustained up to 12
months. Protein mass, a component of muscle mass, was not affected, with only a
slight decrease in water volume observed ... Canagliflozin decreased
extracellular fluid and PV in addition to decreasing fat in the body via calorie
loss resulting from urinary glucose excretion. This study suggested that SGLT2
inhibitors might reduce body weight by regulating fat mass or water distribution
in the body and might have cardiac and renal protective effects by resetting the
homeostasis of fluid balance" - See
canagliflozin at ReliableRXPharmacy.
|
|
